<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002714</url>
  </required_header>
  <id_info>
    <org_study_id>SUMC-G4</org_study_id>
    <secondary_id>CDR0000064550</secondary_id>
    <secondary_id>NCI-H96-0805</secondary_id>
    <nct_id>NCT00002714</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease</brief_title>
  <official_title>A PHASE II TRIAL OF EIGHT-WEEK STANFORD V CHEMOTHERAPY PLUS MODIFIED INVOLVED FIELD RADIOTHERAPY IN FAVORABLE, LIMITED STAGE HODGKIN'S DISEASE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation&#xD;
      therapy in treating patients who have early stage Hodgkin's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the progression-free and overall survival at 5 and 10 years after a&#xD;
      short-term Stanford V regimen comprising mechlorethamine, doxorubicin, vinblastine,&#xD;
      prednisone, vincristine, bleomycin, and etoposide followed by modified involved-field&#xD;
      radiotherapy in patients with favorable, early-stage Hodgkin's disease. II. Determine whether&#xD;
      the early and late toxic effects of treatment can be minimized by avoiding staging&#xD;
      laparotomy, limiting cumulative doses of chemotherapeutic drugs, and reducing the dose and&#xD;
      volume of radiotherapy in these patients. III. Determine the freedom from second disease&#xD;
      progression at 5 and 10 years after treatment and treatment-related toxicity in these&#xD;
      patients. IV. Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive the Stanford V regimen comprising mechlorethamine IV on days 1 and&#xD;
      29; doxorubicin IV and vinblastine IV on days 1, 15, 29, and 43; oral prednisone every other&#xD;
      day on days 1-36 followed by tapered doses; vincristine IV and bleomycin IV on days 8, 22,&#xD;
      36, and 50; and etoposide IV on days 15, 16, 43, and 44. Beginning 2 weeks after completion&#xD;
      of chemotherapy and when blood counts recover, patients undergo modified involved-field&#xD;
      radiotherapy 5 days a week for 3-4 weeks. Quality of life is assessed. Patients are followed&#xD;
      every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1995</start_date>
  <completion_date type="Actual">September 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stanford V regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mechlorethamine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage I-IIA Hodgkin's disease No lymphocyte&#xD;
        predominant disease No stage IA high neck presentation (above the top of the larynx) No&#xD;
        mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter on&#xD;
        chest x-ray No constitutional (B) symptoms at diagnosis No more than 1 extranodal site of&#xD;
        disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 to 60 Performance status: Not specified Hematopoietic:&#xD;
        Granulocyte count at least 2,000/mm3 Platelet count at least 150,000/mm3 Hepatic: Bilirubin&#xD;
        no greater than 2.5 mg/dL Renal: Creatinine no greater than 2 mg/dL Other: No other medical&#xD;
        condition that would preclude study therapy HIV negative No other prior malignancy except&#xD;
        basal cell skin cancer Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No prior therapy for Hodgkin's disease No other concurrent&#xD;
        antineoplastic therapy No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra J. Horning, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2004</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

